Tag : Relapsing

Latest News

Rituximab versus cyclophosphamide as first steroid sparing agent in childhood frequently relapsing and steroid dependent nephrotic syndrome

Newsemia
Kari, JA; Alhasan, KA; Albanna, AS; Safder, OY; Shalaby, M; Bockenhauer, D; El-Desoky, SM; (2020) Rituximab versus cyclophosphamide as first steroid sparing agent in childhood...
Latest News

Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis

Newsemia
John, N; Carroll, A; Brownlee, WJ; Chataway, J; (2019) Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis. [Letter]. Journal of Neurology, Neurosurgery...
Neurology

FDA approves new oral drug to treat relapsing forms of multiple sclerosis

Newsemia
The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease...
Neurology

FDA approves new drug to treat adults with relapsing forms of MS

Newsemia
The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated...
Neurology

Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?

Newsemia
Related Articles Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod? Mult Scler Relat...
Pharma / Biotech

Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.

Newsemia
Related Articles Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2018 Oct 10;27:117-120 Authors:...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy